BG62615B1 - (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase - Google Patents

(imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase

Info

Publication number
BG62615B1
BG62615B1 BG102458A BG10245898A BG62615B1 BG 62615 B1 BG62615 B1 BG 62615B1 BG 102458 A BG102458 A BG 102458A BG 10245898 A BG10245898 A BG 10245898A BG 62615 B1 BG62615 B1 BG 62615B1
Authority
BG
Bulgaria
Prior art keywords
alkyl
alkyloxy
amino
cyano
halogen
Prior art date
Application number
BG102458A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102458A (en
Inventor
Marc G. Venet
Patrick R. Angibaud
Philippe Muller
Gerard C. Sanz
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG102458A publication Critical patent/BG102458A/xx
Publication of BG62615B1 publication Critical patent/BG62615B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG102458A 1995-12-08 1998-05-18 (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase BG62615B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203427 1995-12-08
PCT/EP1996/004515 WO1997021701A1 (fr) 1995-12-08 1996-10-16 Derives de la (imidazol-5-yl)methyl-2-quinoleinone comme inhibiteur de la proteine farnesyle-transferase

Publications (2)

Publication Number Publication Date
BG102458A BG102458A (en) 1999-06-30
BG62615B1 true BG62615B1 (en) 2000-03-31

Family

ID=8220926

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102458A BG62615B1 (en) 1995-12-08 1998-05-18 (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase

Country Status (36)

Country Link
US (3) US6037350A (fr)
EP (2) EP1162201B1 (fr)
JP (1) JP3257559B2 (fr)
KR (1) KR100272676B1 (fr)
CN (1) CN1101392C (fr)
AP (1) AP1108A (fr)
AR (1) AR004992A1 (fr)
AT (2) ATE215541T1 (fr)
AU (1) AU711142B2 (fr)
BG (1) BG62615B1 (fr)
BR (1) BR9610745A (fr)
CA (1) CA2231105C (fr)
CY (1) CY2289B1 (fr)
CZ (1) CZ293296B6 (fr)
DE (2) DE69635966T2 (fr)
DK (2) DK1162201T3 (fr)
EA (1) EA000710B1 (fr)
EE (1) EE03484B1 (fr)
ES (2) ES2260156T3 (fr)
HK (2) HK1012188A1 (fr)
HR (1) HRP960576B1 (fr)
HU (1) HU221227B1 (fr)
IL (1) IL123568A (fr)
MX (1) MX9802068A (fr)
MY (1) MY114444A (fr)
NO (1) NO314036B1 (fr)
NZ (1) NZ320244A (fr)
PL (1) PL184171B1 (fr)
PT (2) PT1162201E (fr)
SI (2) SI0865440T1 (fr)
SK (1) SK283335B6 (fr)
TR (1) TR199800825T2 (fr)
TW (1) TW494101B (fr)
UA (1) UA57717C2 (fr)
WO (1) WO1997021701A1 (fr)
ZA (1) ZA9610254B (fr)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2231105C (fr) * 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Derives de la (imidazol-5-yl)methyl-2-quinoleinone comme inhibiteur de la proteine farnesyle-transferase
PT988038E (pt) * 1997-06-02 2002-12-31 Janssen Pharmaceutica Nv Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
JP2002518387A (ja) * 1998-06-16 2002-06-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
DK1094839T3 (da) * 1998-07-06 2003-08-18 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer med in vivo radiosensibiliserende egenskaber
EE04579B1 (et) * 1998-07-06 2006-02-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
BR9913315A (pt) * 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
AU4925499A (en) * 1998-08-27 2000-03-21 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
WO2000034437A2 (fr) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibiteurs de prenyl-proteine transferase
WO2000034239A2 (fr) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibiteurs de prenyl-proteine transferase
WO2000039082A2 (fr) 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. Derives de 1,2-quinoline condensee
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CN1340051A (zh) 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (fr) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Dérivés de l'imidazole
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
JP2003513940A (ja) * 1999-11-09 2003-04-15 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ヘテロ三量体ｇタンパク質情報の伝達抑制剤と他の抗癌剤とからなる、癌の処置において治療の目的に使用する製品
PT1106612E (pt) * 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ES2262626T3 (es) * 2000-02-04 2006-12-01 Janssen Pharmaceutica N.V. Inhibidores de farnesil proteina transferasa para tratar cancer de mama.
CA2397558A1 (fr) * 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Regime posologique
JP2003525239A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
WO2001064196A2 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de farnesyl proteine transferase et de vinca-alcaloides
CA2397694A1 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Combinaisons d'inhibiteur de farnesyl-proteine transferase
CA2397446A1 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Combinaisons d'inhibiteur de farnesyl proteine transferase et d'agents d'alkylation antitumoraux
US20030100553A1 (en) * 2000-02-29 2003-05-29 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with camptothecin compounds
JP2003525252A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
AU2001244167A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2001064198A2 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons de farnesyl-proteine transferase avec des derives de podophyllotoxine anti-tumoraux
EP1261343A2 (fr) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Inhibiteur de farnesyl proteine transferase associe a des derives nucleosidiques anti-cancereux
EP1261356A2 (fr) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteur de farnesyl proteine transferase et de composes de platine
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024683A1 (fr) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Derives de la quinoleine et de la quinazoline 6-[(phenyle substitue)methyle] inhibiteurs de la farnesyle transferase
JP4974438B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
US7053105B2 (en) 2000-09-25 2006-05-30 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
JP4974439B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
DE60139080D1 (de) * 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
PT1339407E (pt) * 2000-11-28 2006-08-31 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase para o tratamento de doenca inflamatoria do intestino
AU2002218436A1 (en) * 2000-12-19 2002-07-01 Pfizer Products Inc. Crystal forms of 6-((4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl) -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
DE60117847T2 (de) 2000-12-27 2006-11-16 Janssen Pharmaceutica N.V. Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
PT1351954E (pt) * 2000-12-27 2006-09-29 Janssen Pharmaceutica Nv Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
CZ300622B6 (cs) * 2001-03-12 2009-07-01 Janssen Pharmaceutica N. V. Zpusob prípravy 4-(3-chlorfenyl)-6-[(4-chlorfenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-chinolinonu
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
WO2003000705A1 (fr) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Nouveaux quinolines et leurs utilisations
EP1408971A4 (fr) 2001-06-21 2006-01-25 Ariad Pharma Inc Nouvelles quinoleines et leurs utilisations
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US20030134846A1 (en) * 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
AU2002358677B2 (en) 2001-12-19 2008-02-07 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
CA2478813C (fr) * 2002-03-22 2011-10-18 Janssen Pharmaceutica N.V. Derives de 2-quinoleine et de 2-quinazoline substitues par du benzylimidazole utilises en tant qu'inhibiteurs de farnesyl transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2004022097A1 (fr) * 2002-09-05 2004-03-18 Medimmune, Inc. Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
EP1613273B1 (fr) 2003-04-11 2012-06-13 MedImmune, LLC Anticorps il-9 recombinants et leurs utilisations
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
BRPI0412876A (pt) * 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
CN1856470A (zh) * 2003-09-23 2006-11-01 默克公司 喹啉钾通道抑制剂
WO2005089518A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Expression de uch-l1 et cancerotherapie
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
CA2559282A1 (fr) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
WO2005089504A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
WO2005089515A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes de traitement des synucleinopathies
JP5008554B2 (ja) * 2004-05-03 2012-08-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ イミダゾール化合物の製造用のジアステレオ選択的合成方法
JP4917022B2 (ja) * 2004-05-03 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ６−ブロモ−４−（３−クロロフェニル）−２−メトキシ−キノリンを用いるジアステレオ選択的合成方法
ATE398612T1 (de) 2004-05-03 2008-07-15 Janssen Pharmaceutica Nv Diastereoselektive addition von lithiiertem n- methylimidazol an sulfinimine
CA2571421A1 (fr) 2004-06-24 2006-01-05 Nicholas Valiante Composes utilises pour l'immunopotentialisation
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1809326A4 (fr) 2004-10-27 2009-11-04 Medimmune Inc Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
ES2403060T3 (es) 2004-11-05 2013-05-13 Janssen Pharmaceutica Nv Uso terapéutico de inhibidores de la farnesiltransferasa y métodos de control de la eficacia de los mismos.
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1869192B1 (fr) 2005-03-18 2016-01-20 MedImmune, LLC Rearrangement de l'infrastructure d'anticorps
EP1888050B1 (fr) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
WO2007002543A2 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
WO2007110709A2 (fr) * 2005-10-14 2007-10-04 Janssen Pharmaceutica, N.V. Nouvelles préparations iv de tipifarnib
CA2634598A1 (fr) 2005-12-23 2007-07-05 Link Medicine Corporation Traitement de formes de synucleinopathie
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US7414050B2 (en) 2006-04-20 2008-08-19 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
CA2649739C (fr) 2006-04-20 2015-09-01 Janssen Pharmaceutica N.V. Inhibiteurs de la c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
TW201343676A (zh) 2006-08-28 2013-11-01 Kyowa Hakko Kirin Co Ltd 具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
EP2698157B1 (fr) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
KR101591656B1 (ko) 2007-01-10 2016-02-19 엠에스디 이탈리아 에스.알.엘. 폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2703007A1 (fr) 2007-03-30 2014-03-05 MedImmune, LLC Anticorps ayant des profils de déamidation réduits
JO2959B1 (en) 2007-05-14 2016-03-15 جانسين فارماسوتيكا ان. في Mono-hydrochloric salts for histone dacetylase inhibitor
EP2152700B1 (fr) 2007-05-21 2013-12-11 Novartis AG Inhibiteurs du csf-1r, compositions et procédés d'utilisation
JP2010528034A (ja) * 2007-05-23 2010-08-19 アラーガン、インコーポレイテッド 医薬としての（（フェニル）イミダゾリル）メチルキノリニル化合物
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ES2356032T3 (es) 2007-09-14 2011-04-04 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-fenil-3,4,5,6-tetrahidro-2h,1'h-[1,4']bipiridinil-2'-onas 1,3'-disustituidas.
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
MX2010004374A (es) 2007-10-31 2010-04-30 Medimmune Llc Armazones proteinicos.
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009151683A2 (fr) * 2008-03-12 2009-12-17 Link Medicine Corporation Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
MX2011002042A (es) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010057028A2 (fr) * 2008-11-13 2010-05-20 Link Medicine Corporation Traitement de protéinopathies utilisant un inhibiteur de farnésyle transférase
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2373649B1 (fr) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Dérivés d'indole et de benzoxazine comme modulateurs des récepteurs métabotropiques au glutamate
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
CA2784807C (fr) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
AU2011227643A1 (en) 2010-03-16 2012-09-20 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
ES2705719T3 (es) 2010-07-28 2019-03-26 Janssen Diagnostics Llc Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (fr) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
EP2649069B1 (fr) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
JP5963777B2 (ja) 2011-01-31 2016-08-03 ノバルティス アーゲー 新規ヘテロ環誘導体
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
EP2822935B1 (fr) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-terminale (jnk)
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
BR112014028420A2 (pt) 2012-05-16 2017-09-19 Novartis Ag regime de dosagem para um inibidor de quinase pi-3
DK3381943T3 (da) 2012-07-25 2022-05-16 Celldex Therapeutics Inc Anti-kit-antistoffer og anvendelser deraf
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (fr) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Procédé pour la préparation de dérivés d'ester hétérocyclique
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
CA2887129A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs methodes d'utilisation
WO2014062658A1 (fr) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Modulateurs de ror-gamma-t de type quinolinyle à liaison méthylène
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
EP2909193B1 (fr) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Modulateurs de ror-gamma-t de type quinolinyle à liaison phényle
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
CA2892361A1 (fr) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Utilisation d'un inhibiteur wee1 pour traiter un cancer caracterise par de faibles niveaux d'expression de proteines tyrosine et threonine kinases 1 (pkmyt1) associee a la membrane
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2014197849A2 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anticorps anti-c10orf54 et leurs utilisations
EP3906945A3 (fr) 2013-08-26 2022-03-16 BioNTech Research and Development, Inc. Acides nucléiques codant des anticorps humains contre le sialyl-lewis a
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
KR20160070133A (ko) 2013-10-15 2016-06-17 얀센 파마슈티카 엔.브이. RORyt의 알킬 결합 퀴놀리닐 조절제
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
CA2927917C (fr) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Composes heteroaromatiques utiles pour le traitement des maladies proliferatives
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
JP2016539149A (ja) 2013-12-06 2016-12-15 ノバルティス アーゲー アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
WO2015164604A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102614642B1 (ko) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3229838B1 (fr) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anticorps anti-c10orf54 et leurs utilisations
CA2972239A1 (fr) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
CN114504651A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
EP3273966B1 (fr) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
WO2016201370A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
HUE049620T2 (hu) 2015-08-17 2020-09-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
US9815790B2 (en) 2015-08-27 2017-11-14 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
CA2996978A1 (fr) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dependantes
AU2016347881A1 (en) 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
US10875920B2 (en) 2015-12-02 2020-12-29 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2017096017A1 (fr) 2015-12-02 2017-06-08 Stsciences, Inc. Anticorps spécifiques au btla glycosylé (atténuateur de lymphocytes b et t)
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
ES2863730T3 (es) 2016-11-03 2021-10-11 Kura Oncology Inc Inhibidores de la farnesiltransferasa para uso en el tratamiento del cáncer
WO2018103027A1 (fr) 2016-12-08 2018-06-14 杭州领业医药科技有限公司 Forme cristalline de tipifarnib, procédé de préparation et composition pharmaceutique associés
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CA3065300A1 (fr) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methodes de traitement du cancer a l'aide d'anticorps et de molecules se liant de maniere immunospecifique a btn1a1
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019113269A1 (fr) 2017-12-08 2019-06-13 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
KR20210039987A (ko) 2018-05-18 2021-04-12 쿠라 온콜로지, 인크. 티피파닙의 합성
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020190604A1 (fr) 2019-03-15 2020-09-24 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
CA3234276A1 (fr) * 2021-11-30 2023-06-08 Kura Oncology, Inc. Composes macrocycliques ayant une activite inhibitrice de la farnesyltransferase
WO2023141082A1 (fr) * 2022-01-20 2023-07-27 Teva Czech Industries S.R.O. Formes à l'état solide de tipifarnib et leur procédé de préparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101115A (en) * 1980-10-23 1983-01-12 Pfizer Ltd Thromboxane synthetase inhibitors
CA2002864C (fr) * 1988-11-29 1999-11-16 Eddy J. E. Freyne Derives de quinoline, quinazoline ou quinoxaline (1h-azol-1-ylmethyl) substitues
CA2231105C (fr) * 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Derives de la (imidazol-5-yl)methyl-2-quinoleinone comme inhibiteur de la proteine farnesyle-transferase

Also Published As

Publication number Publication date
NO314036B1 (no) 2003-01-20
CY2289B1 (en) 2003-07-04
HK1042482B (zh) 2006-06-09
HUP9900185A2 (hu) 1999-04-28
HRP960576A2 (en) 1998-02-28
HK1042482A1 (en) 2002-08-16
EE9800146A (et) 1998-10-15
KR100272676B1 (ko) 2000-11-15
EP1162201B1 (fr) 2006-03-29
CN1101392C (zh) 2003-02-12
EA000710B1 (ru) 2000-02-28
DK0865440T3 (da) 2002-07-22
ZA9610254B (en) 1998-06-05
DK1162201T3 (da) 2006-07-17
EA199800443A1 (ru) 1998-10-29
ES2175137T3 (es) 2002-11-16
AU7294896A (en) 1997-07-03
BR9610745A (pt) 1999-07-13
PL184171B1 (pl) 2002-09-30
EP0865440B1 (fr) 2002-04-03
EP0865440A1 (fr) 1998-09-23
DE69635966T2 (de) 2006-11-30
HK1012188A1 (en) 1999-07-30
KR19990063891A (ko) 1999-07-26
EP1162201A9 (fr) 2002-04-03
JPH10511405A (ja) 1998-11-04
DE69620445T2 (de) 2002-12-12
CZ157398A3 (cs) 1998-10-14
HRP960576B1 (en) 2002-04-30
TW494101B (en) 2002-07-11
US6037350A (en) 2000-03-14
DE69620445D1 (de) 2002-05-08
EE03484B1 (et) 2001-08-15
SI0865440T1 (en) 2002-08-31
AU711142B2 (en) 1999-10-07
HU221227B1 (en) 2002-08-28
EP1162201A2 (fr) 2001-12-12
CN1203598A (zh) 1998-12-30
ES2260156T3 (es) 2006-11-01
AP1108A (en) 2002-10-02
HUP9900185A3 (en) 1999-11-29
NO980927D0 (no) 1998-03-04
NZ320244A (en) 1999-06-29
CA2231105C (fr) 2005-09-13
AR004992A1 (es) 1999-04-07
SK283335B6 (sk) 2003-06-03
PT1162201E (pt) 2006-08-31
BG102458A (en) 1999-06-30
PL325962A1 (en) 1998-08-17
MX9802068A (es) 1998-08-30
SI1162201T1 (sl) 2006-08-31
TR199800825T2 (xx) 1998-08-21
JP3257559B2 (ja) 2002-02-18
PT865440E (pt) 2002-09-30
CA2231105A1 (fr) 1997-06-19
CZ293296B6 (cs) 2004-03-17
WO1997021701A1 (fr) 1997-06-19
IL123568A0 (en) 1998-10-30
UA57717C2 (uk) 2003-07-15
EP1162201A3 (fr) 2003-11-26
ATE215541T1 (de) 2002-04-15
AP9801257A0 (en) 1998-06-30
DE69635966D1 (de) 2006-05-18
NO980927L (no) 1998-06-08
US6420387B1 (en) 2002-07-16
IL123568A (en) 2001-08-08
ATE321757T1 (de) 2006-04-15
US6169096B1 (en) 2001-01-02
SK70498A3 (en) 1998-10-07
MY114444A (en) 2002-10-31

Similar Documents

Publication Publication Date Title
BG62615B1 (en) (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase
EP1159952A4 (fr) Produits cosmetiques
DE69809754D1 (en) Substituierte 6-phenylphenanthridine
CA2290992A1 (fr) Derives d'(imidazol-5-yl)methyle-2-quinolinone comme inhibiteurs de la proliferation des cellules des muscles lisses
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
ATE219765T1 (de) Indolderivate als cgmp-pde inhibitoren
WO1996016981A3 (fr) Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no
FI965144A0 (fi) Sterolijohdannaiset käytettäviksi meioosin säätelyyn
MXPA02004617A (es) Lipoxin a4 y sus analagos para el tratamiento de ojo reseco.
FR2762514B1 (fr) Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
TR200000414T2 (tr) 2-(4-Aril ya da heteroaril-piperazin-1-ilmetil)-1H-indol türevleri.
MX9709451A (es) Derivados de benzisoxazol e indazol como agentes antipsicoticos.
AU2001259801A1 (en) 3-methoxybenzyl thiourea derivatives and improved lipid compositions containing same
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
WO1998004278A3 (fr) Derives tetrapeptides de dolastatine comme agents antitumoraux
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
SI1196129T1 (sl) Farmacevtski in kozmeticni sestavki, ki obsegajo derivate urokaninske kisline kot odstranjevalce radikalov ali antioksidante
NO973340L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme
AP9801235A0 (en) Erythromycin derivatives.
ATE219775T1 (de) Indolverbindungen, ihre verwendung zum färben und schminken von keratinfasern, sie enthaltende zusammensetzungen und färbeverfanren
ZA965749B (en) Use of allylamines.
NO973242L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti
MXPA02002007A (es) Compuestos de bencimidazol sustituidos con alcoxi, preparaciones farmaceuticas que contienen los mismos, metodos para usarlos.
WO2007071344A3 (fr) Nouveaux composants de couplage